Tempest Therapeutics, Inc. (NASDAQ:TPST) Insider Justin Trojanowski Purchases 7,500 Shares

Tempest Therapeutics, Inc. (NASDAQ:TPST) insider Justin Trojanowski acquired 7,500 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was acquired at an average price of $2.16 per share, for a total transaction of $16,200.00. Following the completion of the transaction, the insider now owns 22,168 shares in the company, valued at approximately $47,882.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempest Therapeutics Trading Down 0.9 %

Tempest Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, hitting $2.12. The company had a trading volume of 539,102 shares, compared to its average volume of 1,020,558. Tempest Therapeutics, Inc. has a 12 month low of $0.17 and a 12 month high of $9.77. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average price is $3.11 and its two-hundred day moving average price is $3.64.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.08. Research analysts expect that Tempest Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC lifted its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,574 shares of the company’s stock after buying an additional 11,689 shares during the period. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent reporting period. Institutional investors own 22.52% of the company’s stock.

Analysts Set New Price Targets

TPST has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, June 20th. William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Piper Sandler restated an “overweight” rating and set a $8.00 price target on shares of Tempest Therapeutics in a research report on Friday, June 21st. Finally, Scotiabank initiated coverage on Tempest Therapeutics in a research report on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $20.75.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.